About Salbutamol + Ipratropium (SALRESP-I) 2.5mL Nebules 35’s

Salbutamol + Ipratropium (SALRESP-I) 2.5mL Nebules is a combination bronchodilator solution formulated for nebulization therapy to relieve and manage acute and chronic respiratory conditions, such as chronic obstructive pulmonary disease (COPD), chronic bronchitis, and bronchial asthma. Each 2.5mL unit-dose nebule contains two active ingredients: Salbutamol, a beta-2 adrenergic agonist, and Ipratropium bromide, an anticholinergic agent. These components work synergistically to relax airway muscles, reduce bronchial secretions, and improve airflow to the lungs.

Salbutamol acts quickly to relieve bronchospasm by stimulating beta-2 receptors in the bronchial smooth muscle, leading to bronchodilation. Ipratropium complements this effect by blocking muscarinic receptors, thus inhibiting the parasympathetic nervous system’s constrictive influence on the airways. Together, they provide fast and sustained relief of breathing difficulties, wheezing, chest tightness, and coughing.

SALRESP-I is especially effective in moderate to severe obstructive airway diseases, particularly when monotherapy is insufficient. This nebulizer solution is suitable for hospital, clinical, and home use, and is widely utilized in both acute exacerbations and maintenance therapy under a physician’s direction.

Indications of Salbutamol + Ipratropium (SALRESP-I) 2.5mL Nebules 35’s

• Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema

• Acute bronchospasm in patients requiring combination therapy

• Bronchial asthma not adequately controlled with a single bronchodilator

• Adjunctive treatment in acute respiratory distress where dual bronchodilation is needed

Dosage and Administration of Salbutamol + Ipratropium (SALRESP-I) 2.5mL Nebules 35’s

Dosage must be individualized by a healthcare professional. Typical dosage:

• Adults and adolescents (12 years and older):
  One nebule (2.5mL) via nebulizer every 6–8 hours as needed

• Children (under 12 years):
  Dosage to be determined by a physician

Administration:

• For inhalation use via a jet nebulizer connected to an air compressor

• Do not mix with other drugs in the nebulizer unless advised by a healthcare provider

• Use immediately after opening

Contraindications of Salbutamol + Ipratropium (SALRESP-I) 2.5mL Nebules 35’s

• Hypersensitivity to Salbutamol, Ipratropium, atropine, or any component of the formulation

• Patients with known hypertrophic obstructive cardiomyopathy or tachyarrhythmias

• Use with caution in:

  • Glaucoma

  • Prostatic hyperplasia

  • Bladder neck obstruction

  • Heart disease

Side Effects of Salbutamol + Ipratropium (SALRESP-I) 2.5mL Nebules 35’s

Common side effects:

• Dry mouth

• Cough or throat irritation

• Headache

• Nausea

• Dizziness

Less common but serious side effects:

• Palpitations or increased heart rate

• Blurred vision or eye pain (signs of acute glaucoma)

• Paradoxical bronchospasm

• Allergic reactions (rash, hives, swelling)

Precautions for Salbutamol + Ipratropium (SALRESP-I) 2.5mL Nebules 35’s

• Avoid contact with eyes to prevent precipitation of angle-closure glaucoma

• Use cautiously in cardiovascular disorders, seizure disorders, and hyperthyroidism

• Not recommended for long-term monotherapy; monitor effectiveness and tolerability

• Always follow dosage and usage instructions as provided by a physician

Storage of Salbutamol + Ipratropium (SALRESP-I) 2.5mL Nebules 35’s

• Store at room temperature (15°C – 30°C)

• Protect from light and freezing

• Use immediately after opening

• Keep out of reach of children